Product Description
Nitrofurantoin is an antibiotic medication that is used for the treatment of uncomplicated lower urinary tract infection. It is effective against most gram-positive and gram-negative organisms. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/29262089/)
Mechanisms of Action: DNA Synthesis Inhibitor,RNA Synthesis Inhibitor,Protein Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: VIATRIS & KG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bangladesh, Congo, Guatemala, India, Pakistan, Zambia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Bacteriuria|Obstetric Labor, Premature|Pregnancy Outcomes|Stillbirth
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ABLE | P3 |
Not yet recruiting |
Stillbirth|Pregnancy Outcomes|Obstetric Labor, Premature|Bacteriuria |
2028-06-01 |